Charl van Zyl

Part of UCB SA, UCB Celltech is a British company that develops novel therapeutic products for humans. The company is based in Slough, UK and was founded in 2006.

Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers.

BSN medical is a multinational company and one of the world leaders in producing and distributing medical products in the segments of plaster, bandages, wound care and compression therapy. Some of its brands are well known - Gypsona ®, Delta-Cast ®, Jobst ® and Tricodur ® - these are vetrouwde names in the medical industry. They have production sites in France, Germany, Mexico, Pakistan, South Africa, United Kingdom and the United States. Sales and marketing its products in major markets by BSN Medical themselves represented as a separate entity. BSN Medical employs approximately 3400 people and has a global turnover of more than 605 million Euros in 2009. BSN medical in April 2001 emerged from a 50:50 joint venture between the companies Beiersdorf AG, Hamburg, and Smith & Nephew plc, London. Purpose of this joint venture was the grouping of geographic and channel strengths in wound care, fracture treatment, physiotherapy and phebologie.

Bausch & Lomb, Inc. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Rochester, NY.

JADO Technologies GmbH develops novel small molecule drugs. It offers drugs based on an unrivalled insight into cell membrane biology and the role of specific cellular domains, including lipid rafts. The firm's technology provides an insight into diverse pathological mechanisms and drives the design of innovative drugs with new modes of action. The company was founded by Teymuras Kurzchalia, Hans-Joachim Knölker, Gary Jennings, Kai Simons and Marino Zerial in 2001 and is headquartered in Dresden, Germany.